Abstract 228P
Background
Clinical profiling studies have shed light on molecular features and mechanisms that modulate response or resistance to immunotherapy but their predictive value remains largely unclear. We (Bareche et al., Annals of Oncology 2022 ) and others (Litchfield et al., Cell 2021 ) have recently curated a compendium of public datasets of DNA, RNA and clinical profiles of patients treated with immunotherapy.
Methods
Leveraging our compendium of immunotherapy clinical datasets, we developed, PredictIO, an open-source meta-analysis pipeline to assess the predictive value of molecular predictors. We first used PredictIO to compute the association between immunotherapy response and established biomarkers, such as tumor mutation burden (TNB) or CD8 gene expression, and a collection of 91 molecular signatures curated from the literature. Second, we used PredictIO for de novo RNA signature discovery pipeline to build a new predictor of immunotherapy response.
Results
Using molecular and clinical profiles of ∼3600 patients across 12 tumor types, our meta-analysis pipeline revealed thatTMB and ∼50% of the gene signatures were significantly predictive of immunotherapy response across tumor types, although their predictive value were strongly dependent on specific tumour types. We next developed a de novo gene expression signature from our pan-cancer analysis and demonstrated its superior predictive value over other biomarkers. To identify novel targets, we computed the T-cell dysfunction score for each gene within PredictIO and their ability to predict dual PD-1/CTLA-4 blockade in mice. Two genes, F2RL1 and RBFOX2, were concurrently associated with worse ICB clinical outcomes, T-cell dysfunction in ICB-naive patients and resistance to dual PD-1/CTLA-4 blockade in preclinical models.
Conclusions
Our study highlights the potential of large-scale meta-analyses in identifying novel biomarkers and potential therapeutic targets for cancer immunotherapy. These initial results, while promising, suffer from severe limitations in terms of data availability for specific cancer types and the lack of frameworks to develop and validate multi-omics predictors of immunotherapy response in a collaborative and scalable way.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
University Health Network.
Disclosure
B. Haibe-Kains: Financial Interests, Personal, Advisory Board: BreakThorugh Cancer, IONIQ Sciences, CQDM; Financial Interests, Personal, Speaker, Consultant, Advisor: Code Ocean.
Resources from the same session
216P - PTCH1 mutation as a potential predictor of immune checkpoint inhibitors in gastrointestinal cancer
Presenter: Yang Tang
Session: Poster session 01
217P - Clinical and molecular features of PTCH1 mutant in solid tumors
Presenter: Xuezheng Li
Session: Poster session 01
218P - Peripheral T cell activation phenotype is associated with clinical outcomes and immune-related adverse events of ipilimumab-nivolumab in advanced hepatocellular carcinoma
Presenter: WON SUK LEE
Session: Poster session 01
219P - Multicentric evaluation of amplicon-based next-generation sequencing solution for local comprehensive molecular tumor profiling
Presenter: Eloisa Jantus Lewintre
Session: Poster session 01
220P - Biomarker of blood age and inflammation in older cancer patients might predict outcome
Presenter: Marcus Vetter
Session: Poster session 01
221P - Peripheral T cell activation phenotype predicts clinical outcomes of atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma
Presenter: Chan Kim
Session: Poster session 01
222P - Therapeutic opportunities for porcupine inhibition in gastrointestinal cancer
Presenter: Natalie Cook
Session: Poster session 01
223P - Artificial intelligence-based pathomics biomarker predict primary resistance to first-line treatment in metastatic colorectal cancers
Presenter: Gianluca Mauri
Session: Poster session 01
224P - Germline HLA-I/II is not associated with clinical outcome but the absence of HLA-A01 or the presence of HLA-B27 supertypes were correlated with improved clinical outcome among patients with NSCLC treated with pembrolizumab in combination with chemotherapy
Presenter: Afaf Abed
Session: Poster session 01
225P - Utility of next-generation sequencing (NGS) in patients with advanced cancer in a low-middle income country
Presenter: Milton Lombana Quinonez
Session: Poster session 01